Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular study

Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy

Sanofi India inks distribution partnership with Emcure to expand reach of its cardiovascular brands

Lupin launches ‘Jeet’ to raise awareness of cardiovascular disease among patients

Jeet will be a trusted partner in cardiovascular care

Lupin Digital Health and American College of Cardiology collaborate for in-home cardiovascular care in India

Riparian Pharmaceuticals inks license and research agreement with Pfizer for cardiovascular programs

Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics

Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases

The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence

AI to shape future outcomes in cardiovascular care, says GlobalData

AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.

Apollo Hospitals integrates cardiovascular risk tool with ConnectedLife digital wellness solutions

The AICVD tool can predict the risk of cardiovascular disease.

Dr. Reddy's to acquire cardiovascular brand Cidmus in India

The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction

Bristol Myers Squibb to demonstrate growing cardiovascular portfolio

New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease